Tagged with Italy,

Italy A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between Venatorx Pharmaceuticals and Menarini, and the country’s drop in healthcare spending.   Stevanato Group Announces Public Offering of Ordinary Shares…

Greece The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic and social impact of the COVID-19 pandemic, but for many biopharma industry leaders they also present an opportunity to tackle…

Italy After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive.   [I am] looking forward to joining the Angelini team and helping to chart the next chapter for [Angelini] Pharma. Jacopo Andreose Abrupt…

Italy Angelini Pharma CEO Pierluigi Antonelli has announced that he is leaving his position with immediate effect, posing the question of what comes next for the leading Italian mid-cap.   Antonelli, profiled by PharmaBoardroom earlier this year, had been in position since 2019 having previously worked his way through the ranks…

Italy The electoral victory of the centre-right coalition in Italy should see far-right firebrand Giorgia Meloni replace former European Central Bank President Mario Draghi as Prime Minister at the end of October 2022, becoming the first woman to ever hold the role. This spirit of change seems also to have permeated…

Italy Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in the country’s National Recovery and Resilience Plan and a priority within its healthcare modernisation plans.   Novel solutions came out…

Italy The Italian system requires drug companies to go through approvals at a national level with the Italian Medicines Agency (AIFA), only to then confront the country’s 21 regional authorities who independently manage the budget for territorial pharmaceutical expenditure and evaluate regional access. According to many industry stakeholders, this lengthy process…

Italy Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European ophthalmic markets, breaking into orphan drugs and adding value in the glaucoma field—and is now seeing its ambitions become a…

Italy Seasoned executive Pierluigi Antonelli went from a career in big pharma to Angelini Pharma, a midsized Italian company that has been undergoing major transformation. He shares the motivation behind the move and the main components of the company’s transformational journey.   Rather than continue on the perhaps easier path he…

Italy Collectively representing almost 400 companies operating in Italy, Farmindustria, Egualia (formerly Assogenerici) and Assobiotec respectively promote the interests of innovative pharmaceutical companies—both foreign and Italian-owned— the generics, biosimilars and value-added medicines sector, and biotech. Massimo Scaccabarozzi, former President of Farmindustria; Michele Uda, director general of Egualia, and Leonardo Vingiani, managing…

Italy As the European Union’s largest beneficiary of the Next Generation EU (NGEU) package, aimed at boosting the EU’s economy following the COVID-19 pandemic, Italy will receive some EUR 235 billion in grants and loans over the lifetime of its National Recovery and Resilience Plan (NRRP). With respect to healthcare, the…

Italy While Italy’s biotech landscape is generally held to be somewhat immature in comparison to more established markets such as Germany, France or the UK, that does not imply a deficit of innovation. On the contrary, the Italian life science scene is increasingly strong when it comes to behind-the-scenes, incremental innovation.…